Eyam Vaccines and Immunotherapeutics Reaches Agreement to License Next-Generation COVID-19 Vaccine Candidates from the University of British Columbia
Eyam Vaccines and Immunotherapeutics (EYAM) today announced that a License Agreement has been reached between the University of British Columbia (UBC) and EYAM for the commercialization of several unique COVID-19 vaccine candidates developed at UBC. This License Agreement represents an important corporate milestone.
